RHONE-POULENC RORER’s LOVENOX LMWH COST IS $23/DAY
RHONE-POULENC RORER's LOVENOX LMWH COST IS $23/DAY average wholesale price, or $161 for a seven-day course of treatment with the low molecular weight heparin product, RPR said April 13. Lovenox (enoxaparin) was approved March 29 for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), following hip replacement surgery ("The Pink Sheet" April 12, T&G-4). There are approximately 250,000 hip replacements performed in the U.S. each year, with an incidence of DVT between 45%-70%. According to RPR, heparins currently are used prophylactically only in approximately "one-third of applicable procedures." A study published in the April 1991 Journal of Surgery found that prophylaxis of DVT and PE "can potentially save 16 deaths per 1,000 patients treated and over $375,000 in health care costs for the same treatment group" or approximately $10,000 per avoided death. Cost to treat a DVT is $2,600 and a PE, $4,758, according to data cited by RPR. Additionally, an RPR Phase III study of 607 hip replacement patients found that those receiving Lovenox were discharged up to two days sooner than patients receiving heparin. By comparison, the cost of other forms of prophylaxis of DVT or PE, such as low-dose warfarin or adjusted-dose heparin, can be higher than LMWH due to required daily, routine blood monitoring, RPR said. Lovenox requires no dosage adjustment for body weight and usually requires no daily blood monitoring. While the standard administration period for Lovenox is seven to 10 days post-surgery, the company said it is assessing the incidence of post-discharge DVT in high-risk patients and is "working on the development of an alternative self-injection device." RPR also is exploring additional indications for enoxaparin.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth